Bausch & Lomb Sold To Valeant Pharmaceuticals For $8.7 Billion
This article was originally published in The Gray Sheet
Executive Summary
In the latest of more than a dozen acquisitions Valeant has made since it was created by a merger with Biovail SA in 2011, Valeant’s purchase of Bausch & Lomb will increase its eye care portfolio substantially.
You may also be interested in...
People Briefs: Calhoun Vision, Benvenue Medical, Urologix, Pentax
Calhoun Vision appoints CEO. Urologix, Benvenue Medical hire CFOs. Pentax Medical promotion.
Valeant Clears Decks, Ups Offer For Allergan – And Says B&L Offers Good Blueprint For Integration
Valeant touted the successes of the B&L acquisition in an effort to prove an Allergan integration would be just as seamless. The increased offer to Allergan came on the heels of Valeant selling its dermatological fillers business to Nestle for $1.4 billion, a move that paves the way for integrating Allergan’s similar portfolio.
Nestlé/Galderma Expands U.S. Dermal-Filler Stake As Valeant Raises Bid For Allergan
Swiss dermatology firm Galderma, soon to be a Nestlé subsidiary, will gain access to the Sculptra dermal filler device and a North American sales presence for four other medical aesthetics products in a $1.4 billion sell-off by Valeant intended to strengthen its position to buy Allergan.